secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001615219-25-000062
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius cuts merger valuation from $4.6M to $2.31M; legacy holders drop to 7.6%
--------------------------------------------------------------------------------

- Parent Valuation reduced to $2.31M, down from $4.6M in original Jan 2025 merger agreement.
- Legacy Salarius stockholders retention cut to 7.6% from 14.1%; Decoy holders rise to 92.4%.
- Exchange ratio change adds ~17M more shares to Decoy stockholders at closing.
- Series A Preferred includes one-year anti-dilution protection and Nasdaq conversion restrictions.
- Automatic conversion conditioned on Nasdaq listing approval and stockholder vote per Rule 5635.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000062/0001615219-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000062/flks-20250610.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer